The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
Open accessAbstract
GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the mechanisms underlying GLP-1R agonist–mediated vasodilation. Two crossover studies were conducted: 36 participants with type 2 diabetes received subcutaneous exenatide or placebo for 11 days and EF, and glucose and lipid responses to breakfast and lunch were determined; and 32 participants with impaired glucose tolerance (IGT) or diet-controlled type 2 diabetes had EF measured before and after intravenous exenatide, with or without the GLP-1R antagonist exendin-9. Mechanisms of GLP-1R agonist action were studied ex vivo on human subcutaneous adipose tissue arterioles and endothelial cells. Subcutaneous exenatide increased postprandial EF independent of reductions in plasma glucose and triglycerides. Intravenous exenatide increased fasting EF, and exendin-9 abolished this effect. Exenatide elicited eNOS activation and NO production in endothelial cells, and induced dose-dependent vasorelaxation and reduced high-glucose or lipid-induced endothelial dysfunction in arterioles ex vivo. These effects were reduced with AMPK inhibition. In conclusion, exenatide augmented postprandial EF in subjects with diabetes and prevented high-glucose and lipid-induced endothelial dysfunction in human arterioles. These effects were largely direct, via GLP-1R and AMPK activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro/ex vivo studies conducted on endothelial cells showed that GLP-1RAs such as exenatide and liraglutide stimulate endothelial NO production and endothelial nitric oxide synthase (eNOS) activation, eliciting vasodilatation through activation of the GLP-1 receptor-dependent AMP-activated protein kinase (AMPK)/protein kinase B (Akt)/eNOS signaling pathway [48–50].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [48]
In the citing paper
“Human studies provide conflicting information about the effect of GLP-1 or stable analogues on endothelial function.212-217”
From The Vasculature in Prediabetes (2018) · cites this paper as [213]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I. V., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,522
Prognostic Value of Coronary Vascular Endothelial Dysfunction
Halcox, J. P. J., Schenke, W. H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M. A., Nour, K. R. A., & Quyyumi, A. A. (2002) · Circulation · doi:10.1161/01.cir.0000025404.78001.d8 · Cited by 1,385
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“Whereas earlier studies in rodents implicated a role of a non-GLP-1R–mediated pathway activated mainly by GLP-1 degradation products (19,20), more recent in vitro and in vivo data indicate a direct action via endothelial GLP-1Rs (22,24).”
BackgroundImpaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
Williams, S. B., Cusco, J. A., Roddy, M.-A., Johnstone, M. T., & Creager, M. A. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00522-6 · Cited by 1,014
Bonetti, P. O., Pumper, G. M., Higano, S. T., Holmes, D. R., Kuvin, J. T., & Lerman, A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.062 · Cited by 974
McVeigh, G. E., Brennan, G. M., Johnston, G. D., McDermott, B. J., McGrath, L. T., Henry, W. R., Andrews, J. W., & Hayes, J. R. (1992) · Diabetologia · doi:10.1007/bf00429099 · Cited by 916
Brachial Flow-Mediated Dilation Predicts Incident Cardiovascular Events in Older Adults
Yeboah, J., Crouse, J. R., Hsu, F., Burke, G. L., & Herrington, D. M. (2007) · Circulation · doi:10.1161/circulationaha.106.678276 · Cited by 902
Gokce, N., Keaney, J. F., Hunter, L. M., Watkins, M. T., Menzoı́an, J. O., & Vita, J. A. (2002) · Circulation · doi:10.1161/01.cir.0000012543.55874.47 · Cited by 782
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude
Kuvin, J. T., Patel, A. R., Sliney, K. A., Pandian, N. G., Sheffy, J., Schnall, R. P., Karas, R. H., & Udelson, J. E. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00094-2 · Cited by 772
Cited by
Sorted by citations
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,205
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Stehouwer, C. D. A. (2018) · Diabetes · doi:10.2337/dbi17-0044 · Cited by 317
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Metadata
- Authors
- Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., D’Alessio, D., Migrino, R. Q., & Reaven, P. D.
- Affiliations
- Department of Medicine, Phoenix VA Health Care System, Phoenix, AZ
- Phoenix VA Health Care System (US)
- Duke University (US)
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-26
- Volume
- 64
- Issue
- 7
- Pages
- 2624-2635
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC4477348
- OpenAlex
- W2130583827
- Cited by
- 174
- References
- 52
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 20 · 2023: 11 · 2022: 20 · 2021: 14 · 2020: 6 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 12 · 2015: 4
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R21HL-092344-01)
- U.S. Department of Veterans Affairs (1I01CX000598, BLRD I01BX007080)
- American Diabetes Association (1-10-CT-31)
- Amyloidosis Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- exenatide, GLP-1 receptor agonists, endothelial dysfunction, vasodilation, type 2 diabetes, impaired glucose tolerance, AMPK, endothelial nitric oxide synthase, nitric oxide, high glucose, hypertriglyceridemia, endothelial cells
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Blood Glucose, Cells, Cultured, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Peptides, Triglycerides, Vasodilation, Venoms, Receptors, Glucagon, Cross-Over Studies, Endothelial Cells, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
